Other News

Silk Road Medical Strengthens TCAR Portfolio with Launch of ENROUTE Transcarotid Neuroprotection System PLUS

Uncategorized by Comments are Disabled

SUNNYVALE, Calif., April 02, 2024 (GLOBE NEWSWIRE) — Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the launch of its ENROUTE® Transcarotid Neuroprotection System PLUS (“NPS PLUS”), a key component of the TCAR® portfolio. This next generation device builds upon the prior ENROUTE Transcarotid Neuroprotection System to deliver smoother arterial sheath insertion, greater flow precision, and a simplified prep experience for surgical teams, all while maintaining unparalleled neuroprotection during the TCAR procedure.

Continue Reading →

Transverse Medical Appoints David C. Blowers to Board of Directors, Dr. Rahul Sharma as Independent Member, Carl St. Bernard rejoins Board.

Financial by 0 comments

DENVER–(BUSINESS WIRE)–Point-Guard Protected™ Safeguard the Brain, Treat the Heart. Transverse Medical, Inc., developer of the POINT-GUARD™ Cerebral Embolic Protection medical device to protect the patient from stroke during Transcatheter Aortic Valve Replacement (TAVR) has reorganized the Board of Directors following the recent closing of a Series B1 financing. Transverse Medical […]

Continue Reading →

Protembis Announces First Patient Enrolled in the PROTEMBO IDE Pivotal Trial

Coronary/Structural Heart by 0 comments

NEW YORK & AACHEN, Germany–(BUSINESS WIRE)–Protembis GmbH (Protembis), a privately-held emerging cardiovascular medical device company, announced today the enrollment of the first patient in the PROTEMBO Investigational Device Exemption (IDE) Pivotal Trial (NCT05873816). The trial will enroll between 250-500 randomized patients undergoing transcatheter aortic valve replacement (TAVR) in the USA […]

Continue Reading →

Vektor Medical Announces Publication of vMap Study Results in Journal of Cardiovascular Electrophysiology

Rhythm by 0 comments

SAN DIEGO–(BUSINESS WIRE)–Vektor Medical, a pioneer in non-invasive, AI-based arrhythmia analysis technology, today announced the publication of data in the Journal of Cardiovascular Electrophysiology (JACE) demonstrating vMap’s ability to reduce the time from mapping to treatment, procedure duration, and fluoroscopy when treating cardiac arrhythmia patients with ablation therapy. “A 22.6% reduction in […]

Continue Reading →

HeartSciences to Present at the LD Micro Invitational XIV Conference

Coronary/Structural Heart by Comments are Disabled

Southlake, TX, April 02, 2024 (GLOBE NEWSWIRE) — Heart Test Laboratories, Inc. d/b/a HeartSciences  (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that Chief Executive Officer Andrew Simpson is scheduled to present at the LD Micro Invitational XIV Conference on Tuesday April 9, 2024 at 5:00pm ET at the Sofitel New York. Mr. Simpson will also be hosting one-on-one meetings through the conference.

Continue Reading →

AngioDynamics Announces Settlement of All Patent Litigation with C.R. Bard, Inc.

Financial by 0 comments

LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it has entered into a settlement agreement with Becton, Dickinson and Company (“BD”) […]

Continue Reading →

LifeTech Scientific Corporation Announced 2023 Annual Results: International Business Achieved a Robust Growth, Innovation at the Core to Drive the Solid Development

Financial by Comments are Disabled

SHENZHEN, China, April 2, 2024 /PRNewswire/ — LifeTech Scientific Corporation (the “Company” or “Lifetech”, Stock code: 1302.HK), a company specializing in minimally invasive interventional medical devices for cardio-cerebrovascular and peripheral vascular diseases, together with its…

Continue Reading →

Innovating “Treadmill Exercise Test AI-Assisted Interpretation System,” CMUH(Taiwan) Timely Saves More Patients with Severe Myocardial Infarction

Coronary/Structural Heart by Comments are Disabled

TAICHUNG, Taiwan, April 2, 2024 /PRNewswire/ — The treadmill exercise test (TET) is an important tool for diagnosing coronary artery disease (CAD), but limited by time spent for the manual interpretation of a dozen charts and the challenges in identifying minor deviations. Traditionally,…

Continue Reading →

Arch Biopartners Adds Three New Clinical Sites into the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Coronary/Structural Heart by Comments are Disabled

TORONTO, April 02, 2024 (GLOBE NEWSWIRE) — Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that three additional clinical sites in Turkey have joined the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.

Continue Reading →
1 … 275 276 277 278 279 … 1,332